RPRX: financial statements from SEC — TradeAlmanac

RPRX

Royalty Pharma plc: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31 Mar 2026	30 Sept 2025	30 Jun 2025	31 Mar 2025	30 Sept 2024	30 Jun 2024
Revenue	631M	609M	579M	568M	565M	537M
Research and development	40M	51M	301M	51M	500,000	500,000
Selling, general and administrative	159M	119M	180M	111M	57M	55M
Operating expenses	68M	182M	369M	34M	−170M	268M
Operating income	563M	427M	210M	534M	735M	270M
Pre-tax income	468M	444M	91M	433M	806M	194M
Income tax	0	0	0	0	0	0
Net income	295M	288M	30M	238M	544M	102M
Earnings per share	0.67	0.67	0.07	0.55	1.22	0.23
Earnings per share, diluted	0.67	0.67	0.07	0.55	1.21	0.23
Weighted average shares	437M	432M	424M	435M	448M	451M
Weighted average shares, diluted	557M	560M	562M	578M	593M	597M

Balance sheet

Metric	31 Mar 2026	31 Dec 2025	30 Sept 2025	30 Jun 2025	31 Mar 2025	31 Dec 2024	30 Sept 2024	30 Jun 2024
Cash and equivalents	586M	619M	939M	632M	1.09B	929M	950M	1.76B
Current assets	1.43B	1.53B	1.85B

Cash flow

Metric	31 Mar 2026	31 Mar 2025
Operating cash flow	718M	596M
Investing cash flow	−478M	504M
Share buybacks	50M	709M
Financing cash flow	−273M	−941M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator